MetaStat, Inc.

Equities

MTST

US59140A2033

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:17:00 27/07/2023 pm IST			5-day change	1st Jan Change
0.0001 ^USD	+9,900.00%		-.--%	-.--%

2018	MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	CI
2017	MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	CI

MetaStat, Inc. Appoints Michael J. Donovan, PhD, MD as Chief Medical Officer

August 17, 2015 at 06:48 pm IST

MetaStat, Inc. announced the appointment of Michael J. Donovan, PhD, MD as acting Chief Medical Officer. Dr. Donovan joins the Company as the research and development program expands in breadth and depth for its
proprietary driver-based diagnostic platform. Dr. Donovan joins the Company as the research and development program expands in breadth and depth for its proprietary driver-based diagnostic platform.

Latest news about MetaStat, Inc.

MetaStat, Inc. Presents Positive Data Showing Inhibition of the MENA-Pathway Reduces Cancer Cell Dissemination and Paclitaxel Resistance in Aggressive Cancer	21/18/21	CI
MetaStat, Inc. Appoints Renato T. Skerlj as Member of its Scientific and Clinical Advisory Board	03/17/03	CI
MetaStat, Inc. announced that it has received $2.57 million in funding	03/17/03	CI
MetaStat, Inc. announced that it expects to receive $7 million in funding	23/17/23	CI
MetaStat Announces Completion of Second Milestone of its Pilot Research Project with Celgene Corporation	19/17/19	CI
MetaStat, Inc. Appoints Paul Billings to its Board of Directors, Effective as of May 24, 2017	01/17/01	CI
MetaStat, Inc. Announces Management Changes	08/17/08	CI
MetaStat, Inc. Announces Board Changes	08/17/08	CI
MetaStat, Inc. Announces Resignation of Martin J. Driscoll from the Board of Directors	29/17/29	CI
MetaStat, Inc. Presents Supportive Data for the Role of Mena Protein Isoforms in Tumor Dissemination at the 2017 American Association of Cancer Research Annual Meeting	06/17/06	CI
MetaStat, Inc. Receives Additional State Clinical Laboratory Licenses	19/16/19	CI
MetaStat, Inc. Presents Positive Data from Two Clinical Studies of Metasite Breast at 2016 San Antonio Breast Cancer Symposium	13/16/13	CI
MetaStat, Inc. announced that it has received $2.61 million in funding	21/16/21	CI
MetaStat, Inc. cancelled the transaction announced on October 10, 2014	10/16/10	CI
MetaStat, Inc. and Celgene Corporation Enter into Amendment to Pilot Materials Transfer Agreement	06/16/06	CI
MetaStat, Inc. Announces Resignation of Johan M. Spoor as Board of Directors	08/16/08	CI
MetaStat, Inc. announced that it expects to receive $20 million in funding	31/16/31	CI
MetaStat, Inc. announced that it has received $0.5 million in funding	08/16/08	CI
MetaStat, Inc. announced that it expects to receive $5 million in funding	26/16/26	CI
MetaStat, Inc. Names Jerome B. Zeldis as Vice Chairman of the Board of Directors	27/16/27	CI
Metastat, Inc. Appoints Anthony Shuber as Head of Diagnostic Research and Development	24/16/24	CI
MetaStat, Inc. announced that it has received $0.98 million in funding from Dolphin Management Inc.	15/16/15	CI
MetaStat, Inc. Announces Resignation of Mark Gustavson as Vice President of Diagnostics	12/16/12	CI
MetaStat, Inc. announced that it expects to receive $1 million in funding from Dolphin Management Inc, and other investors.	12/16/12	CI
MetaStat Announces Completion of Analytical Validation Study of its MenaCalc Cancer Diagnostic Platform	26/16/26	CI

Chart MetaStat, Inc.

Duration

Period

More charts

Company Profile

MetaStat, Inc. is a precision medicine company. The Company's therapeutic focus targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. The Company's product development programs are focused on developing drug candidates and companion diagnostic tests that target the MENA pathway. Its pipelines include MENA Diagnostic Assay and MetaSite Breast Assay. The MENA diagnostic assay is a tissue-based quantitative immunofluorescence (QIF) test that measures expression of the pro-metastatic MENA protein splice-variant which is associated with poor outcomes and metastasis in early-stage breast cancer (ESBC) and squamous cell carcinoma of the Lung. MetaSite Breast is an immunohistochemistry test (IHC) that measures micro-anatomical intravasation sites (TMEM) at blood vessels within the tumor microenvironment which are clinically validated as prognostic markers of metastasis in hormone receptor-positive (HR+) ESBC.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
METASTAT, INC.	-.--%	587
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
BIO-TECHNE CORPORATION	+0.04%	12.16B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research